The World Anti-Doping Agency (WADA) has declared its intention to challenge the recent decision that cleared Jannik Sinner in a doping case, which is a significant milestone. Following two positive tests for the banned substance clostebol in March, the agency is seeking a period of ineligibility for Sinner ranging from one to two years.
The 23-year-old Italian, who recently claimed his second Grand Slam title at the US Open and is currently competing in Beijing, has consistently denied any wrongdoing. The International Tennis Integrity Agency (ITIA) previously concluded that Sinner did not act with fault or negligence, accepting his explanation that the drug entered his system via a spray used by his physiotherapist during treatment for a cut.
WADA said in a statement that it disagreed with the ITIA’s conclusions and that Sinner’s decision to be cleared of all charges did not follow the relevant regulations. The agency emphasized that it does not seek to disqualify any results achieved by Sinner, except for those already affected by the initial tribunal ruling.
As this case progresses to the Court of Arbitration for Sport (CAS), WADA has opted to refrain from further comments until a decision is reached. Clostebol is classified as an anabolic agent and is prohibited at all times under WADA regulations.
Despite the controversies surrounding his positive tests, Jennik Sinner has remained focused on his performance on the court. After his US Open victory over Taylor Fritz, he acknowledged the mental toll of the situation but expressed pride in his ability to stay concentrated during matches. “It was and it’s still on my mind,” Sinner admitted. “It’s not that it’s gone, but when I’m on court, I try to focus on the game and handle the situation the best possible way.”
The decision to clear Sinner has sparked skepticism among some of his peers, who have voiced concerns about potential preferential treatment based on his stature in the sport. As the case unfolds, it will be crucial to observe how the tennis community responds to these developments and the final ruling from CAS.